Cantor Fitzgerald Investment Advisors L.P. Sells 2,450 Shares of AbbVie Inc. $ABBV

Cantor Fitzgerald Investment Advisors L.P. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 50.0% in the third quarter, Holdings Channel reports. The firm owned 2,450 shares of the company’s stock after selling 2,450 shares during the period. Cantor Fitzgerald Investment Advisors L.P.’s holdings in AbbVie were worth $641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Granite Islands Private Wealth LLC boosted its holdings in shares of AbbVie by 3.1% in the 3rd quarter. Granite Islands Private Wealth LLC now owns 9,068 shares of the company’s stock worth $2,365,000 after buying an additional 272 shares during the last quarter. Patriot Investment Management Group Inc. grew its position in AbbVie by 17.1% during the third quarter. Patriot Investment Management Group Inc. now owns 4,574 shares of the company’s stock valued at $1,197,000 after buying an additional 668 shares during the period. ACT Advisors LLC. grew its position in AbbVie by 6.7% during the third quarter. ACT Advisors LLC. now owns 1,801 shares of the company’s stock valued at $471,000 after buying an additional 113 shares during the period. Ellsworth Advisors LLC bought a new position in AbbVie during the third quarter valued at about $245,000. Finally, NFSG Corp increased its holdings in AbbVie by 2.6% during the third quarter. NFSG Corp now owns 9,304 shares of the company’s stock worth $2,434,000 after buying an additional 238 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Trading Up 0.7%

ABBV stock opened at $285.32 on Friday. The firm has a 50 day moving average of $262.74 and a 200-day moving average of $239.22. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The firm has a market capitalization of $504.10 billion, a P/E ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts predict that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Analyst Ratings Changes

ABBV has been the topic of several research reports. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. BMO Capital Markets raised their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. HSBC upped their price objective on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada reissued an “outperform” rating and set a $280.00 price objective on shares of AbbVie in a report on Tuesday. Finally, Argus raised their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.